China Isotope & Radiation Corporation $(CIRC.UK)$ has announced a strategic cooperation agreement with Qianlong International Holdings Limited. The collaboration aims to promote and expand the application of boron neutron capture therapy technology (BNCT) and other nuclear medical innovations. This partnership will focus on establishing oncology treatment institutions in China, enhancing the use of nuclear medical equipment, radiopharmaceuticals, and intelligent nuclear medicine solutions both domestically and internationally. The agreement underscores a commitment to advancing nuclear medicine industries through technological innovation, benefiting public health on both sides of the strait. Qianlong International, based in Hong Kong, specializes in biotechnology and digital health investments.